galantamine hydrobromide

ApprovedSmall molecule

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

galantamine hydrobromide is one of 122 small molecule programs targeting Frontotemporal Dementia. It is currently in Approved.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

Frontotemporal DementiaActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Vascular DementiaActive, not recruiting

DementiaActive, not recruiting

Frontotemporal DementiaPhase 2

Active, not recruiting

Cognitive ImpairmentPhase 3

Active, not recruiting

Vascular DementiaPhase 3

Active, not recruiting

DementiaApproved

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

galantamine hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Approved

4 4

Xarelto

WWim Janssens

Phase 3

1 5

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 6

Provigil

NNuvo Research GmbH

Phase 3

1 7

Viagra

VViatris Specialty LLC

Phase 3

1 8

Donepezil Hydrochloride

Eisai

Phase 3

3 9

Namenda

AbbVie

Phase 2

5 10

Statins

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alzheimer's Disease8 trials

Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00253214·973 enrolled

Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00338117·554 enrolled

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00216593·415 enrolled

Show 5 more trials

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00253188·653 enrolled

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00253201·636 enrolled

A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00253227·387 enrolled

A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00216502·254 enrolled

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT00297362·344 enrolled

Cognitive impairment4 trials

A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00240695·724 enrolled

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00236574·974 enrolled

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00077727·107 enrolled

Show 1 more trial

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00236431·1,063 enrolled

Dementia1 trial

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00216515·102 enrolled

Frontotemporal Dementia1 trial

A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00416169·41 enrolled

Vascular Dementia1 trial

A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00261573·593 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for galantamine hydrobromide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — galantamine hydrobromide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for galantamine hydrobromide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

galantamine hydrobromide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alzheimer's Disease8 trials

Cognitive impairment4 trials

Dementia1 trial

Frontotemporal Dementia1 trial

Vascular Dementia1 trial

References

Drug Info

Quick Facts

Related News